Format

Send to

Choose Destination
Science. 1995 Oct 20;270(5235):475-80.

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

Author information

1
National Center for Human Genome Research, National Institutes of Health (NIH), Bethesda, MD 20892, USA.

Abstract

In 1990, a clinical trial was started using retroviral-mediated transfer of the adenosine deaminase (ADA) gene into the T cells of two children with severe combined immunodeficiency (ADA- SCID). The number of blood T cells normalized as did many cellular and humoral immune responses. Gene treatment ended after 2 years, but integrated vector and ADA gene expression in T cells persisted. Although many components remain to be perfected, it is concluded here that gene therapy can be a safe and effective addition to treatment for some patients with this severe immunodeficiency disease.

PMID:
7570001
DOI:
10.1126/science.270.5235.475
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center